Neumora Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Neumora Therapeutics Inc 's ROA in the second quarter of 2026?
Neumora Therapeutics Inc recorded a cumulative net loss of $-213 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -131.32%.

However, within the Healthcare sector 783 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4330, from total ROA ranking in the first quarter of 2026 at 4992.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-44.04 %	-39.86 %	-39.39 %	-49.18 %	-44.02 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-213	-222	-237	-236	-252
Return On Assets (TTM)	-131.32 %	-119.15 %	-111.69 %	-97.17 %	-88.08 %
NMRA's Total Ranking	# 4330	# 4992	# 4377	# 4388	# 4401
Total Assets (TTM) in million	125	154	191	178	224
Seq. Total Assets Change	-18.6 %	-19.46 %	7.43 %	-20.55 %	-12.52 %
Seq. Net Income Change	-	-	-	-	-

NMRA's 5 Years Annual ROA >> Back to NMRA Management Effectiveness >> Compare NMRA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 122
Sector	# 784
Overall	# 4314

Return On Assets Statistics
High	Average	Low
-19.25 %	-76.21 %	-131.32 %
(Mar 31 2024)		(Jun 30 2026)

Financial Statements
Neumora Therapeutics Inc 's Assets	$ 125 million	NMRA's Balance sheet
Neumora Therapeutics Inc 's Income	$ -43 million	Quarterly NMRA's Income Statement
NMRA's Income by Division		See NMRA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	FY	FY
Y / Y Total Assets Change	-39.39 %	-35.92 %	-	-	-
Total Assets in million	191	315	492	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-237	-244	-236	0	0
Annual Return On Assets	-124.02 %	-77.34 %	-47.96 %	-	-

NMRA's 5 Years Annual ROA >> Back to NMRA Management Effectiveness >> Compare NMRA ROA to its Competitors

More Return On Assets Ratios
NMRA's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NMRA's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NMRA's Competitors
Subscribers only: Roa for Neumora Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for NMRA's Customers

You may also want to know
NMRA's Roi	NMRA's Inventory Turnover Ratio	NMRA's Growth Rates	NMRA's Dividend Comparisons
	NMRA's Profitability Ratios	NMRA's Asset Turnover Ratio	NMRA's Dividend Growth
NMRA's Roe	NMRA's Valuation Ratios	NMRA's Financial Strength Ratios	NMRA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:42:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.